CD274 and non-small cell lung carcinoma: In an NSCLC monotherapy expansion cohort (anti–PD-1/PD-L1 refractory patients n = 23, anti–PD-1/PD-L1 responders n = 14), 1 PR was reported, in a patient from the anti–PD-1/PD-L1 responder cohort.49 A synergistic effect is expected with INCAGN02390 in combination with anti–PD-1 therapy.